Article Figures & Data
Figures
- Figure 1.
Average price per claim for statins
- Figure 2.
Average price per claim for proton pump inhibitors
- Figure 3.
Average price per claim for angiotensin-converting enzyme inhibitors
- Figure 4.
Average price per claim for selective serotonin reuptake inhibitors
Tables
DRUG CLASSES REASON FOR EXCLUSION Tumour necrosis factor-α inhibitors Differing intraclass prescribing indications HMG-CoA reductase inhibitors None Proton pump inhibitors None Antineovascularization agents Single medication in class Adrenergics and other agents for obstructive airway disease Differing intraclass prescribing indications Natural opium alkaloids Differing intraclass dosing frequency Angiotensin-converting enzyme inhibitors None Selective serotonin reuptake inhibitors None Diazepines, oxazepines, thiazepines, and oxepines Differing intraclass prescribing indications Other antidepressants Differing intraclass prescribing indications HMG-CoA—β-hydroxy-β-methylglutaryl-coenzyme A.
MEDICATION NAME PRESCRIPTION VOLUME AMOUNT SPENT, $ Simvastatin 1 476 449 35 586 574.87 Lovastatin 89 062 2 622 148.26 Pravastatin 473 513 10 999 674.29 Fluvastatin 59 953 2 211 319.35 Atorvastatin 7 501 174 126 341 799.24 Rosuvastatin 5 881 601 98 630 998.33 Total 15 481 752 276 392 514.34 MEDICATION NAME PRESCRIPTION VOLUME AMOUNT SPENT, $ Omeprazole 1 312 644 34 081 259.91 Pantoprazole 4 836 094 115 848 301.09 Lansoprazole 1 268 096 27 780 761.44 Rabeprazole 3 199 095 40 648 239.20 Esomeprazole 256 867 12 701 013.80 Total 10 872 796 231 059 575.44 MEDICATION NAME PRESCRIPTION VOLUME AMOUNT SPENT, $ Captopril 27 187 696 785.76 Enalapril 625 610 11 390 235.24 Lisinopril 526 898 6 599 590.85 Perindopril 2 220 774 73 681 469.31 Ramipril 5 486 052 54 231 798.03 Quinapril 341 827 12 601 968.09 Benazepril 7463 307 759.66 Cilazapril 109 289 1 514 273.09 Fosinopril 213 088 3 282 334.77 Trandolapril 351 299 10 990 045.05 Total 9 909 487 175 296 259.85 MEDICATION NAME PRESCRIPTION VOLUME AMOUNT SPENT, $ Fluoxetine 625 267 13 597 382.91 Citalopram 3 311 486 37 830 125.40 Paroxetine 939 262 16 954 851.49 Sertraline 1 250 437 19 088 540.17 Fluvoxamine 135 599 2 116 457.98 Escitalopram 2 203 617 83 597 346.67 Total 8 465 668 173 184 704.62 - Table 6.
Determination of “nonswitching” constant: The nonswitching constant was the proportion of patients who, when prescribed their first medication, were not likely to change to another intraclass medication.
CLASS AVERAGE TOLERABILITY, % TOLERABILITY FOR LEAST EXPENSIVE MEDICATION IN CLASS, % CHOSEN NONSWITCHING CONSTANT Statins 94.443 97.543 94
Proton pump inhibitor
80–954485–9545
8744
80Angiotensin-converting enzyme inhibitors 9233 9546 92
Selective serotonin reuptake inhibitors60–6547
9747
60–65
60 MEDICATION NAME CURRENT RATIONAL PRESCRIBING (ESTIMATED) PRESCRIPTION VOLUME MARKET SHARE, % PRESCRIPTION VOLUME MARKET SHARE, % Simvastatin 1 476 449 10 3143 0 Lovastatin 89 062 1 189 0 Pravastatin 473 513 3 52 390 0 Fluvastatin 59 953 0 12 0 Atorvastatin 7 501 174 48 873 171 6 Rosuvastatin 5 881 601 38 14 552 847 94 MEDICATION NAME CURRENT RATIONAL PRESCRIBING (ESTIMATED) PRESCRIPTION VOLUME MARKET SHARE, %* PRESCRIPTION VOLUME MARKET SHARE, %* Omeprazole 1 312 644 12 69 586 1 Pantoprazole 4 836 094 44 347 929 3 Lansoprazole 1 268 096 12 1 739 647 16 Rabeprazole 3 199 095 29 8 698 237 80 Esomeprazole 256 867 2 17 396 0 ↵* Market share does not add to 100% owing to rounding.
- Table 9.
Prescription volumes and market shares for angiotensin-converting enzyme inhibitors
MEDICATION NAME CURRENT RATIONAL PRESCRIBING (ESTIMATED) PRESCRIPTION VOLUME MARKET SHARE, %* PRESCRIPTION VOLUME MARKET SHARE, %* Captopril 27 187 0 8 0 Enalapril 625 610 6 373 0 Lisinopril 526 898 5 729 338 7 Perindopril 2 220 774 22 6 0 Ramipril 5 486 052 55 9 116 728 92 Quinapril 341 827 3 6 0 Benazepril 7463 0 6 0 Cilazapril 109 289 1 58 347 1 Fosinopril 213 088 5 4668 0 Trandolapril 351 299 4 6 0 ↵* Market share does not add to 100% owing to rounding.
- Table 10.
Prescription volumes and market shares for selective serotonin reuptake inhibitors
MEDICATION NAME CURRENT RATIONAL PRESCRIBING (ESTIMATED) PRESCRIPTION VOLUME MARKET SHARE, %* PRESCRIPTION VOLUME MARKET SHARE, %* Fluvoxamine 135 599 2 812 704 10 Escitalopram 2 203 617 24 86 668 1 Fluoxetine 625 267 7 130 033 2 Citalopram 3 311 486 37 5 079 401 60 Paroxetine 939 262 10 325 082 4 Sertraline 1 250 437 14 2 031 760 24 ↵* Market share does not add to 100% owing to rounding.
DRUG CLASS TOTAL CURRENT ANNUAL SPENDING, $ RATIONAL ANNUAL SPENDING, $ SAVINGS, $ Statins 276 392 514 260 248 249 16 144 265 Proton pump inhibitors 231 059 575 159 634 040 71 425 535 Angiotensin-converting enzyme inhibitors 175 296 260 100 145 896 75 150 364 Selective serotonin reuptake inhibitors 173 184 705 113 711 852 59 472 853 Total 855 933 054 633 740 038 222 193 017 DRUG CLASS TOTAL CURRENT ANNUAL SPENDING, $ RATIONAL ANNUAL SPENDING, $ SAVINGS, $ Statins 588 069 179 553 719 680 34 349 499 Proton pump inhibitors 537 347 849 371 241 953 166 105 896 Angiotensin-converting enzyme inhibitors 350 592 520 200 291 793 150 300 727 Selective serotonin reuptake inhibitors 494 813 443 324 891 006 169 922 437 Total 1 970 822 991 1 450 144 432 520 678 559
In this issue
Jump to section
Related Articles
Cited By...
- L'éléphant environnemental dans la clinique : les médicaments
- The environmental elephant in the office: medications
- Engaging physicians to prescribe more cost-effectively: Blueprint for change
- Inciter les médecins à prescrire en se souciant davantage des coûts: Stratégie de changement
- The 1% versus the 99%: Reducing unnecessary health care costs